Incyte Issues Tepid 2026 Revenue Outlook, Spotlight on Opzelura and Jakafi Patent Risk
Incyte projected 2026 sales well below analyst expectations, citing Opzelura underperformance even after a strong fourth quarter. The company also provided Jakafi sales guidance that tops estimates but highlights looming patent expiration risks for its top-selling product in 2028. Shares slipped in premarket trading following the forecast.